| Kyorin Pharmaceutical Co., Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120100212 | TABLET HAVING HOLLOW STRUCTURE - A water floatable tablet, which is either:
| 04-26-2012 |
| 20120029032 | MATRIX-TYPE SUSTAINED RELEASE PREPARATION CONTAINING BASIC ADDITIVE - Disclosed is a matrix-type sustained release preparation containing a basic drug unstable against an acid as an active pharmaceutical ingredient, wherein the decomposition of the basic drug unstable against the acid can be prevented and therefore the pH-dependent release can be reduced. A hardly water-soluble basic normal salt is added to a matrix-type sustained release preparation containing a basic drug that is unstable against an acid. | 02-02-2012 |
| 20110077427 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINOALCOHOL DERIVATIVE - Disclosed is a preparation method which makes it possible to produce an aminoalcohol derivative having a high optical purity and to enable the large scale synthesis thereof at a low price. | 03-31-2011 |
| 20110071204 | PERCUTANEOUS ABSORPTION PREPARATION - This present invention provides a percutaneous absorption type pharmaceutical preparation which includes 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the active ingredient and a backbone for transdermal system, and satisfies at least one of the following conditions (1) and (2). The pharmaceutical preparation of the present invention enables absorption of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide, which has a low ability to be absorbed from the skin, from the skin into the body continuously and efficiently.
| 03-24-2011 |
| 20110021636 | METHOD FOR CRYSTALLIZATION OF 2-AMINO-2-[2-[4-(3-BENZYLOXYPHENYLTHIO)-2-CHLOROPHENYL]-ETHYL]-1,3-PROPAN- EDIOL HYDROCHLORIDE - A method for highly efficiently preparing high purity crystals of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]-ethyl]-1,3-propanediol hydrochloride. The method involves dissolving 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol in a mixed solvent comprising a solvent in which its hydrochloride is highly soluble and a solvent in which its hydrochloride is less soluble, to prepare a solution of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol; and then adding hydrochloric acid to the resulting solution with stirring, to crystallize the hydrochloride of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]ethyl]-1,3-propanediol. | 01-27-2011 |
| 20110002988 | ORALLY RAPIDLY DISINTEGRATING TABLET COMPRISING IMIDAFENACIN - Provided herein is an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. | 01-06-2011 |
| 20100324081 | PREVENTIVE, INHIBITOR OR REMEDY FOR CEREBRAL ANEURYSM COMPRISING IBUDILAST AS AN ACTIVE INGREDIENT - Herein provided is an agent for the prevention of cerebral aneurysm, for the control of the formation thereof or for the treatment thereof, which comprises Ibudilast as an effective component. | 12-23-2010 |
| 20100323090 | METHOD FOR PRODUCTION OF ORALLY RAPIDLY DISINTEGRATING TABLET COMPRISING IMIDAFENACIN AS ACTIVE INGREDIENT - The present invention herein provides an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. | 12-23-2010 |
| 20100280096 | TREATMENT OF INFLUENZA - The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense RNA thereof. | 11-04-2010 |
| 20100102474 | METHOD FOR PREPARING SUSTAINED RELEASE TABLET - Herein provided is a method for easily preparing a sustained release tablet which contains an orally administrable medicinal component, while maintaining the uniformity of the content of the medicinal component. | 04-29-2010 |
| 20090299075 | PROCESS FOR PRODUCING MUSCARINE RECEPTOR ANTAGONIST AND INTERMEDIATE THEREFOR - The industrial production of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide, a urinary incontinence remedy, necessitates elimination of problems concerning the use of a synthetic adsorbent, e.g., HP-20, the efficiency of operation with the same, purification efficiency, etc. An acid salt, e.g., hydrochloride or phosphate, of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide or a hydrate of any of these salts is used as an intermediate. This intermediate is neutralized and then purified. Thus, high-purity 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide is easily obtained in satisfactory yield. The industrial-scale production process has been thus established. | 12-03-2009 |
| 20090247752 | GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION, ITS PRODUCTION AND METHOD FOR SUPPRESSING FORMATION OF PRECIPITATE DURING STORAGE AT LOWER TEMPERATURE AND AT THE TIME OF FREEZING AND THAWING OF THE AQUEOUS LIQUID PREPARATION - There is provided an aqueous liquid preparation comprising 0.65 to 2 w/v % of Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof as free Gatifloxacin, and at least 0.5 w/v % of at least one of the ingredient selected from the group consisting of phosphoric acid, malonic acid, nicotinamide and a salt thereof, wherein a pH thereof is 5.8 to 6.9. In the aqueous liquid preparation, the solubility of Gatifloxacin is increased and the formation of a precipitate during storage at a lower temperature and at the time of freezing and thawing of the aqueous liquid preparation is suppressed by incorporating at least one of the ingredient selected from the group consisting of nicotinamide, caffeine, methylglucamine and Methyl parahydroxybenzoate into the aqueous liquid preparation. | 10-01-2009 |
| 20090247543 | GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION - There is provided an aqueous liquid preparation comprising Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof, phosphoric acid or a salt thereof, and xanthan gum, wherein a pH thereof is 5.5 or more and less than 7.0. The aqueous liquid preparation has improved intraocular penetration of Gatifloxacin. Further, the formation of a precipitate during storage at a lower temperature and at the time of freezing and thawing of the aqueous liquid preparation is suppressed by incorporating at least one of the ingredient selected from the group consisting of nicotinamide, caffeine, methylglucamine, methyl parahydroxybenzoate and a salt thereof into the aqueous liquid preparation. | 10-01-2009 |
| 20090137685 | Therapeutic Agent for Inflammatory Bowel Disease Containing as Active Ingredient 2-Amino-1,3-Propanediol Derivative, or Method for Treating Inflammatory Bowel Disease - A novel therapeutic and prophylactic agent for inflammatory bowel diseases and a method for treating inflammatory bowel diseases. | 05-28-2009 |
| 20080207941 | Process for Producing 2-Amino-2-[2-[4-(3-Benzyloxyphenylthio)-2-Chlorophenyl]Ethyl]-1,3-Propanediol Hydrochloride and Hydrates Thereof, and Intermediates in the Production Thereof - A process for the industrial production of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride (Compound I), an effective immunosuppressant. | 08-28-2008 |
